Atricure - ATRC STOCK NEWS

AtriCure, Inc. (Nasdaq: ATRC) reported a strong second quarter 2021, with revenue reaching $71.4 million, up 74.8% from the previous year. U.S. revenue saw a significant increase of 78.4% to $60.1 million, driven by recovery in cardiac procedures following COVID-19 disruptions. The company received FDA approval for the EPi-Sense® System, enhancing its treatment offerings. Adjusted EBITDA loss improved to $2.7 million. The 2021 revenue guidance has been updated to $270 to $275 million, reflecting 31% to 33% growth, although pandemic uncertainties remain a concern.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), has announced its participation in the Canaccord 41^st Annual Growth Conference. The company will present on August 11, 2021, at 8:00 a.m. Eastern Time. Interested participants can access the live and archived audio webcast on AtriCure’s website. AtriCure is known for its innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® for left atrial appendage management, addressing the needs of over 33 million Afib sufferers globally.

AtriCure, Inc. (Nasdaq: ATRC) has announced the release date for its second quarter 2021 financial results, set for August 4, 2021. A conference call will take place at 4:30 p.m. ET on the same day, allowing stakeholders to discuss the results. AtriCure specializes in innovative treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, with its technologies widely used by healthcare professionals. The company aims to improve outcomes for the over 33 million people affected by Afib globally.

AtriCure, Inc. (Nasdaq: ATRC) announced the election of Deborah H. Telman and Maggie Yuen to its Board of Directors. Ms. Telman brings over 20 years of executive experience, notably at Organon and Sorrento Therapeutics, with expertise in legal affairs and compliance. Ms. Yuen, currently CFO at Penumbra, has extensive experience in finance and operations within the medical device sector. Both executives aim to advance AtriCure's mission in treating atrial fibrillation and enhancing growth opportunities in the healthcare space.

AtriCure, Inc. (Nasdaq: ATRC) announced FDA approval for the EPi-Sense® System, which treats long-standing persistent atrial fibrillation (Afib). The CONVERGE™ trial demonstrated a 29% absolute efficacy improvement at 12 months and a 35% improvement at 18 months for patients using hybrid AF therapy compared to traditional methods. The therapy reduces ablation times by over 40 minutes, enhancing lab efficiency. With over three million patients affected in the U.S., this treatment aims to change care standards for difficult Afib cases, promising improved outcomes and long-term freedom from arrhythmias.

AtriCure, Inc. (Nasdaq: ATRC) reported first quarter 2021 revenue of $59.3 million, an increase of 11.4% year-over-year. U.S. revenue grew 15.7% to $50.3 million, driven by increasing sales in key product categories, while international revenue declined 8.1% to $9 million due to COVID-19 restrictions. The gross profit rose to $44.5 million with a gross margin of 75.1%. The company reported a net loss of $15.9 million, or $0.38 per share, an improvement from $0.42 per share a year earlier. AtriCure projects full year 2021 revenue between $252 million and $256 million.

AtriCure, Inc. (Nasdaq: ATRC) has appointed B. Kristine Johnson as Board Chair. Scott Drake and Mark Lanning will not seek re-election in May 2021. Johnson, who has been on the board since 2017, is President of Affinity Capital Management and has extensive experience in the healthcare sector, including a 17-year career at Medtronic. Drake, who has served on AtriCure's Board since 2013, and Lanning, a board member since 2006, have both contributed significantly to the company's growth.

AtriCure, a leader in Afib treatments, will release its Q1 2021 financial results on April 27, 2021. The company will also host a conference call at 4:30 PM ET to discuss these results, accessible by calling (844) 884-9951 (domestic) or (661) 378-9661 (international), using conference ID 3349395. AtriCure is recognized for innovative solutions, including the FDA-approved Isolator Synergy Ablation System for persistent Afib and the widely used AtriClip Left Atrial Appendage Exclusion System.

AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Oppenheimer 31st Annual Healthcare Conference. The presentation is scheduled for March 16, 2021, at 1:10 p.m. Eastern Time. AtriCure offers innovative solutions, including the Isolator® Synergy™ Ablation System, the first FDA-approved device for treating persistent Afib, and the AtriClip® Left Atrial Appendage Exclusion System, the most widely sold LAA management device globally. For more details, visit AtriCure's investor page.